News Archives - Ziccum

Ziccum AB (publ) ansöker om konkurs

Styrelsen i Ziccum AB (publ) (”Ziccum” eller ”Bolaget”) har idag, den 10 januari 2025 beslutat att ansöka om att Bolaget ska försättas i konkurs för att hantera den uppkomna finansiella situationen. Konkursansökan kommer att ges in till Lunds tingsrätt.

Beslutet baseras på en grundlig genomgång av olika alternativ mot bakgrund av den nyligen uppkomna finansiella situationen och styrelsen har efter en samlad bedömning kommit fram till att bolagets finansiering är otillräcklig för att uppfylla utestående förpliktelser och att driva verksamheten framåt. Bolaget genomförde under det 4:e kvartalet 2024 en företrädesemission som inbringade ett avsevärt lägre kapitaltillskott än förväntat. Samtidigt bedöms andra källor till finansiering otillräckliga för att realisera Bolagets fortsatta drift, emedan finansiären Global Corporate Finance (”GCF”) valt att avvisa bolagets förfrågan om fortsatt finansiering enligt ingånget avtal.

Med anledning av ovanstående har styrelsen i Ziccum idag beslutat att ansöka om konkurs vid Lunds tingsrätt.

Ziccum beklagar att Bolaget är oförmöget att fortsatt driva teknik- och affärsutveckling för sin patenterade läkemedelsteknologi LaminarPace®.

Om Ziccum

Ziccum utvecklar LaminarPace®, en unik metod för torkning av biologiska läkemedel och vacciner i rumstemperatur. Metoden bygger på massöverföring istället för värmeöverföring. Tekniken licensieras ut till utvecklare och tillverkare av vaccin och biologiska läkemedel inom den globala läkemedelsindustrin. Genom att minska den stress som den aktiva substansen utsätts för under torkningen erbjuder LaminarPace® en unik möjlighet att ta fram termostabila biologiska läkemedel med partikel-teknologi i en torr pulverberedning. Dessa är enkla att hantera och transportera och lämpar sig utmärkt för nya administreringssätt. Tekniken har framgångsrikt tillämpats på mRNA, peptider, proteiner, antikroppar, lipider och enzymer, samt på hjälpämnen och adjuvanter, och lämpar sig väl för industriell tillämpning. Ziccum är noterat på Nasdaq First North Growth Market.

Ziccum AB (publ) ansöker om konkurs

Ziccum AB (publ) files for bankruptcy

The board of directors of Ziccum AB (publ) (”Ziccum”or the ”Company”) has today, 10 January 2025, resolved to file for bankruptcy on behalf of the Company to manage the financial situation that has occurred. The application for bankruptcy will be submitted to Lund District Court.

The decision is based on a thorough assessment of alternatives, considering the current financial situation, and the board has reached the overall conclusion that the Company does not have enough financing to fulfil outstanding obligations and continue operations. The Company completed a rights issue in fourth quarter 2024 where the proceeds gained were significantly lower than expected. Meanwhile, other sources of financing are judged inadequate to maintain continued Company operations, as the current investor Global Corporate Finance (“GCF) has chosen to decline the Company’s request for continued financing according to the existing agreement.

Considering the above, the board of directors of Ziccum has today decided to file for bankruptcy at Lund District Court.

Ziccum regrets the inability of the Company to pursue its continued technology and business development based on LaminarPace®, its patented pharmaceutical technology platform.

About Ziccum

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Ziccum AB (publ) files for bankruptcy

Ziccum resolves on a directed issue of shares and provides an update on its financial situation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES THAN THOSE REQUIRED BY SWEDISH LAW. SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW.

The board of directors of Ziccum AB (publ) (“Ziccum” or the “Company”) has called for a third investment tranche in accordance with the previously communicated financing agreement between the Company and Global Corporate Finance (“GCF”), and in connection therewith resolved to carry out a directed share issue. As communicated by the Company on 12 December 2024, the outcome of the Rights Issue finalized in December 2024 was materially below Ziccum’s expectations. In light of this financial predicament, the present directed share issue (executed under the existing Share Subscription Facility Agreement with GCF) is vital to the Company’s continued operations at this point in time. Any uncertainty as to whether GCF may assume its obligations in accordance with the Financing Agreement or other failure to promptly execute the present Directed Share Issue would put the company in a material financial distress.

On 22 January 2024, the Company announced in a press release, inter alia, that it had entered into a long-term financing agreement with GCF (the “Financing Agreement”), pursuant to which Ziccum has the unilateral right to call for investments from GCF in separate tranches totaling the equivalent of USD 3 million over a period of 30 months, thereby securing rapid access to capital injections to cover the Company’s budgeted costs until 2025.

The board of directors of Ziccum has now called for a third investment tranche under the Financing Agreement and has today resolved, based on the authorization granted by the Extraordinary General Meeting on 12 November 2024, to carry out a directed share issue to GCF of a total of 4,698,588 shares amounting to approximately SEK 2,202,420.84 (the “Directed Share Issue”). The subscription price in the Directed Share Issue has been set at SEK 0.47 per share in accordance with the terms and conditions set out in the Financing Agreement and as further described in the Company’s press release dated 22 January 2024.

Prior to the Directed Share Issue, the Company’s board of directors has made an overall assessment and carefully considered the possibility of raising capital through a new share issue with pre-emption rights for the Company’s existing shareholders. However, the board of directors considers that there are reasons to deviate from the shareholders’ pre-emption rights given that the Directed Share Issue can be carried out in a more time-efficient manner, at a lower cost and with less complexity than a rights issue. In addition, the board of directors considers the speed and predictability of the procedure with the Directed Share Issue, in light of the Financing Agreement, as a significant advantage, as it is deemed to facilitate the Company to act in the current market and to safeguard the Company’s interests, in line with the Company’s strategy and overall objectives. Taking into account the above, the board of directors considers, after an overall assessment, that the Directed Share Issue is the most appropriate and favorable option for Ziccum and all its shareholders. Any uncertainty as to whether GCF may assume its obligations in accordance with the Financing Agreement or other failure to promptly execute the present Directed Share Issue would put the company in material financial distress.

As the subscription price in the Directed Share Issue has been determined in accordance with the terms and conditions set out in the Financing Agreement, it is the board of directors’ assessment that the subscription price has been secured on market terms.

Through the Directed Share Issue, the number of outstanding shares and votes in Ziccum increases by 4,698,588 from a total of 29,534,352 to a total of 34,232,940 shares and votes.

The share capital increases by approximately SEK 783,098.000001 from SEK 4.922.392,000005 SEK approximately SEK 5,705,490.000006. Further, the Directed Share Issue entails a dilution of approximately 15.91 per cent of the number of shares and votes in the Company following the completion of the Directed Share Issue.

Important information
The publication, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions and persons in the jurisdictions where this press release has been published or distributed should inform themselves about and observe such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer or an invitation to acquire or subscribe for any securities in Ziccum in any jurisdiction, neither from Ziccum nor from anyone else.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the ”Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared by the Company and published on the Company’s website in connection with the Directed Share Issue.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable law or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in contravention of this guidance may constitute a breach of applicable securities laws.

In the United Kingdom, this document and other materials relating to the securities referred to herein are only being distributed and directed to, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, ”qualified investors” (as defined in section 86(7) of the Financial Services and Markets Act 2000) who are (i) persons who have professional experience in matters relating to investments and who fall within the definition of ”investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”); or (ii) ”high net worth entities” as referred to in Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ”relevant persons”). An investment or investment activity to which this communication relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action based on this announcement and should not act or rely on it.

The Company considers that it carries out activities worthy of protection under the Swedish Screening of Foreign Direct Investments Act (2023:560) (the “FDI Act”). In accordance with the FDI Act, the Company must inform prospective investors that the Company’s activities may fall within the scope of the regulation and that the investment may be notifiable. In the event that an investment is notifiable, it must be notified to the Inspectorate for Strategic Products (ISP) prior to it being carried out.

Forward-looking statements
This press release contains forward-looking statements that reflect the Company’s intentions, beliefs or expectations regarding the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the fact that they contain expressions such as ”believes”, ”expects”, ”anticipates”, ”intends”, ”estimates”, ”will”, ”may”, ”assumes”, ”should”, ”could” and, in each case, negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialise or that they are accurate. Because these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcomes may differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements in this press release. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct and any reader of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein speak only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revision to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or First North’s Rulebook for Issuers.

About Ziccum

Ziccum resolves on a directed issue of shares and provides an update on its financial situation

Ziccums företrädesemission är registrerad – omvandling av BTU till aktier och teckningsoptioner

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG, KRÄVA REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN SÅDANA SOM FÖLJER AV SVENSK RÄTT. SE ÄVEN AVSNITTET ”VIKTIG INFORMATION” NEDAN.

Ziccum AB (publ) (”Ziccum” eller ”Bolaget”) har genomfört en företrädesemission av units, bestående av aktier och teckningsoptioner av serie TO 6, där teckningsperioden löpte ut den 10 december 2024 (”Företrädesemissionen”). Företrädesemissionen har registrerats hos Bolagsverket den 27 december 2024. Sista dag för handel med betalda tecknade units (”BTU”) är den 3 januari 2025. Utsökningsdag är den 8 januari 2025, varefter BTU omvandlas till aktier och teckningsoptioner av serie TO 6 den 10 januari 2025. Aktier och teckningsoptioner beräknas distribueras till tecknares VP-konton/depåer den 10 januari 2025.

Företrädesemissionen har registrerats hos Bolagsverket den 27 december 2024. Sista dag för handel med BTU är den 3 januari 2025. Utsökningsdag är den 8 januari 2025, varefter BTU omvandlas till aktier och teckningsoptioner av serie TO 6 den 10 januari 2025. Aktier och teckningsoptioner beräknas distribueras till tecknares VP-konton/depåer den 10 januari 2025.

Rådgivare
Vator Securities AB agerar finansiell rådgivare och emissionsinstitut och Fredersen Advokatbyrå AB agerar legal rådgivare till Ziccum i samband med Företrädesemissionen.

Viktig information
Informationen i detta pressmeddelande innehåller inte och utgör inte ett erbjudande att förvärva, teckna eller på annat sätt handla med units, aktier, teckningsoptioner eller andra värdepapper i Ziccum. Inga åtgärder har vidtagits eller kommer att vidtas för att tillåta ett erbjudande till allmänheten i någon annan jurisdiktion än Sverige. Inbjudan till berörda personer att teckna units, aktier eller teckningsoptioner i Ziccum har endast skett genom det prospekt som offentliggjorts av Bolaget den 20 november 2024. Prospektet har godkänts och registrerats av Finansinspektionen samt offentliggjorts på Bolagets hemsida. Finansinspektionens godkännande av prospektet ska inte uppfattas som ett godkännande av Bolagets aktier, teckningsoptioner eller andra värdepapper. Detta pressmeddelande är inte ett prospekt enligt definitionen i prospektförordningen (EU) 2017/1129 (”Prospektförordningen”) och har inte blivit godkänt av någon tillsynsmyndighet i någon jurisdiktion. Detta pressmeddelande varken identifierar eller föreslår, eller utger sig för att identifiera eller föreslå, de risker (direkta eller indirekta) som kan vara förenade med en investering i aktier, teckningsoptioner eller andra värdepapper i Ziccum. För att investerare fullt ut ska förstå de potentiella risker och fördelar som är förknippade med ett beslut att delta i Företrädesemissionen bör ett investeringsbeslut endast fattas baserat på informationen i Prospektet. Investerare uppmanas därför att ta del av Prospektet i dess helhet.

Offentliggörande, publicering eller distribution av detta pressmeddelande kan i vissa jurisdiktioner vara föremål för legala restriktioner och personer i de jurisdiktioner där detta pressmeddelande har offentliggjorts eller distribuerats bör informera sig om och följa sådana legala restriktioner. Mottagaren av detta pressmeddelande är ansvarig för att använda detta pressmeddelande och informationen häri i enlighet med tillämpliga regler i respektive jurisdiktion. Detta pressmeddelande utgör inte ett erbjudande om, eller inbjudan att, förvärva eller teckna några värdepapper i Ziccum i någon jurisdiktion, varken från Ziccum eller från någon annan.

Detta pressmeddelande utgör inte ett erbjudande om eller inbjudan att förvärva eller teckna värdepapper i USA. De värdepapper som omnämns häri får inte säljas i USA utan registrering eller undantag från registrering enligt den vid var tid gällande U.S. Securities Act från 1933 (”Securities Act”) och får inte erbjudas eller säljas i USA utan registrering eller undantag från, eller i en transaktion som inte omfattas av, registreringskraven i Securities Act. Det finns ingen avsikt att registrera några värdepapper som omnämns i detta pressmeddelande i USA eller att lämna ett offentligt erbjudande av sådana värdepapper i USA. Informationen i detta pressmeddelande får inte offentliggöras, publiceras, kopieras, reproduceras eller distribueras, direkt eller indirekt, helt eller delvis, i eller till USA, Australien, Hongkong, Japan, Kanada, Nya Zeeland, Schweiz, Singapore, Sydafrika, Sydkorea, Ryssland, Belarus eller någon annan jurisdiktion där sådant offentliggörande, publicering eller distribution av denna information skulle stå i strid med gällande lagstiftning eller där sådan åtgärd är föremål för legala restriktioner eller skulle kräva ytterligare registrering eller andra åtgärder än de som följer av svensk rätt. Åtgärder i strid med denna vägledning kan utgöra brott mot tillämplig värdepapperslagstiftning.

Bolaget anser att det bedriver skyddsvärd verksamhet enligt lagen (2023:560) om granskning av utländska direktinvesteringar (”FDI-lagen”). I enlighet med FDI-lagen måste Bolaget informera presumtiva investerare om att Bolagets verksamhet kan falla inom regleringens tillämpningsområde och att investeringen kan vara anmälningspliktig. I det fall en investering är anmälningspliktig måste den, innan den genomförs, anmälas till Inspektionen för Strategiska Produkter (ISP). Varje investerare bör rådfråga en oberoende juridisk rådgivare om den eventuella tillämpningen av FDI-lagen i förhållande till Företrädesemissionen för den enskilde investeraren.

Framåtblickande uttalanden
Detta pressmeddelande innehåller framåtriktade uttalanden som återspeglar Bolagets avsikter, bedömningar eller förväntningar avseende Bolagets framtida resultat, finansiella ställning, likviditet, utveckling, framtidsutsikter, förväntad tillväxt, strategier och möjligheter samt de marknader inom vilka Bolaget är verksamt. Framåtriktade uttalanden är uttalanden som inte avser historiska fakta och kan identifieras genom att de innehåller uttryck som ”anser”, ”förväntar”, ”förutser”, ”avser”, ”uppskattar”, ”kommer”, ”kan”, ”antar”, ”bör”, ”kan” och, i varje enskilt fall, negationer därav, eller liknande uttryck. De framåtriktade uttalandena i detta pressmeddelande är baserade på olika antaganden, varav många är baserade på ytterligare antaganden. Även om Bolaget anser att de antaganden som återspeglas i dessa framåtriktade uttalanden är rimliga, kan det inte garanteras att de kommer att förverkligas eller att de är korrekta. Eftersom dessa antaganden baseras på antaganden eller uppskattningar och är föremål för risker och osäkerheter, kan de faktiska resultaten eller utfallen skilja sig väsentligt från dem i de framåtblickande uttalandena av en rad olika skäl. Sådana risker, osäkerheter, oförutsedda händelser och andra viktiga faktorer kan leda till att faktiska händelser skiljer sig väsentligt från de förväntningar som uttrycks eller antyds i de framåtriktade uttalandena i detta pressmeddelande. Bolaget garanterar inte att de antaganden som ligger till grund för de framåtriktade uttalandena i detta pressmeddelande är korrekta och läsare av detta pressmeddelande bör inte fästa otillbörlig vikt vid de framåtriktade uttalandena i detta pressmeddelande. Den information, de åsikter och de framåtriktade uttalanden som uttrycks eller antyds i detta pressmeddelande gäller endast per dagen för detta pressmeddelande och kan komma att ändras. Varken Bolaget eller någon annan åtar sig att se över, uppdatera, bekräfta eller offentligt meddela någon revidering av något framåtriktat uttalande för att återspegla händelser som inträffar eller omständigheter som förekommer avseende innehållet i detta pressmeddelande, såvida inte detta krävs enligt lag eller tillämpliga noteringsregler.

Om Ziccum

Ziccums företrädesemission är registrerad – omvandling av BTU till aktier och teckningsoptioner

Ziccum’s rights issue registered – conversion of BTU into shares and warrants

Ziccum AB (publ) (“Ziccum” or the “Company”) has completed a rights issue of units, consisting of shares and warrants of series TO 6, where the subscription period ended on 10 December 2024 (the ”Rights Issue”). The Rights Issue was registered with the Swedish Companies Registration Office on 27 December 2024. The last day of trading in paid subscribed units (“BTU”) will be 3 January 2025. The record date is 8 January 2025, after which the BTU’s will be converted into shares and warrants of series TO 6 on 10 January 2025. Shares and warrants are expected to be distributed to the investors’ VPC accounts/custody accounts on 10 January 2025.

The Rights Issue was registered with the Swedish Companies Registration Office on 27 December 2024. The last day of trading in BTU’s will be 3 January 2025. The record date is 8 January 2025, after which the BTU’s will be converted into shares and warrants of series TO 6 on 10 January 2025. Shares and warrants are expected to be distributed to the investors’ VPC accounts/custody accounts on 10 January 2025.

Advisors
Vator Securities AB is acting as financial advisor and issuing agent and Fredersen Advokatbyrå AB is acting as legal advisor to Ziccum in connection with the Rights Issue.

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in units, shares, warrants or other securities in Ziccum. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for units, shares or warrants in Ziccum has only been made through the prospectus published by the Company on 20 November 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and published on the Company’s website. The Swedish Financial Supervisory Authority’s approval of the prospectus shall not be construed as an approval of the Company’s shares, warrants or other securities. This press release is not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 (“Prospectus Regulation”) and has not need approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Ziccum. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety.

The publication, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions and persons in the jurisdictions where this press release has been published or distributed should inform themselves about and observe such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer or an invitation to acquire or subscribe for any securities in Ziccum in any jurisdiction, neither from Ziccum nor from anyone else.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable law or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in contravention of this guidance may constitute a breach of applicable securities laws.

The Company considers that it carries out protection-worthy activities under the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar) (the “FDI Act”). According to the FDI Act, the Company must inform presumptive investors that the Company’s activities may fall under the regulation and that the investment may be subject to mandatory filing. If an investment is subject to mandatory filing, it must prior to its completion, be filed with the Inspectorate of Strategic Products (the ISP). investor should consult an independent legal adviser on the possible application of the Swedish FDI Act in relation to the participation in the Rights Issue by the individual investor.

Forward-looking statements
This press release contains forward-looking statements that reflect the Company’s intentions, beliefs or expectations regarding the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the fact that they contain expressions such as ”believes”, ”expects”, ”anticipates”, ”intends”, ”estimates”, ”will”, ”may”, ”assumes”, ”should”, ”could” and, in each case, negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialise or that they are accurate. Because these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcomes may differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements in this press release. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct and any reader of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein speak only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revision to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or applicable listing rules.

About Ziccum

Ziccum’s rights issue registered – conversion of BTU into shares and warrants

Closing an intense year, building Ziccum to a new level

At Ziccum, we just held a concluding session to wrap up 2024, celebrated Christmas and looked forward into 2025. We are very proud to summarize the milestones achieved during 2024; the company has gained a new level of technology understanding and industry recognition.

Initial aspirations to address the mRNA/LNP field, initiated in 2023, have been met well beyond expectations. When it comes to proof of concept, we now have proven the successful LaminarPace® application on successive levels regarding this most difficult modality, mRNA in LNP formulation; in cell testing, in animal testing, in partner projects and in our internal development. Furthermore, we have proof generated that we can create inhalable mRNA, something much desired by industry, but challenging.

As a result, we have a solid pipeline of dialogues we take forward, like reported. There are several leading so called Big Pharma Corporations where we are in scoping stage, and several high calibre Biotech companies where we now are having dialogues for inhaled medications. Several confidentiality agreements were signed only this final week before the holidays. These inhalation discussions are particularly important: for these projects, the ability to achieve robust, dry powder forms is not only beneficial and saving a lot of money but a must for dry powder inhalation. We look forward to taking dialogues forward to signed contracts in the near future.

The interesting inhalation edge of our technology also brought us into a large consortium of mRNA experts around the world, and this high calibre group managed to submit a grant application together in record time, in November.

During the year we concluded three feasibility studies for important partners, with good and excellent results. The Ziccum team stepped up to this, taking on the dialogue with leading mRNA experts and successfully delivering solid read-outs.

It is important to bring the equipment development further, and it has been rewarding to build in-depth understanding of the LaminarPace® performance in 2024. Designing the customized nebulizer design and setting the path for the product outtake in continuous operation, ensuring the platform to operate efficiently for any biologic compound to be processed, forced us to run extensive testing with a lot of learnings as a result. In parallel, our colleagues in Zürich, the ZHAW institute, supported the development by 3D-simulations ensuring a good plan for the continuous production plan, and we completed the first 1.0 digital twin version.

The large amounts of data generated made it possible to build our IP protection further, and the three new patent families were complemented with a lot of data in the spring, for both process parameters and relevant product formulation, before publication in October this year. All in all, we have a very different position now, not only knowing how the LaminarPace® process performs, but also why – and how to optimize it.

Securing capital for our continued efforts is critical. Grants and revenues from feasibility studies have provided valuable contributions, but more capital will be required. The most recent rights issue yielded less than we had anticipated, to a large extent due to factors that were out of company control. As a consequence, the board of directors and I are carefully overseeing our short-to-midterm tactics, reviewing our finances to ensure careful spending and capital planning.

The industry interest for Ziccum’s technology is substantial and increasing. It is of great value to ensure that Ziccum and LaminarPace® can help making new and better patient treatments possible.

Together with the entire team, let me extend our very best wishes for

A Merry Christmas & A Happy New Year,

Ann Gidner, CEO

Lund, 23 December 2024

About Ziccum

Closing an intense year, building Ziccum to a new level

Ziccum announces outcome of rights issue

Ziccum AB (publ) (“Ziccum” or the “Company”) announces that the Company's rights issue of units (the “Rights Issue”), in which the subscription period ended on 10 December 2024, has been completed. The final count shows that 6,449,634 units, corresponding to approximately 18.4 per cent of the Rights Issue, have been subscribed for with unit rights (including subscription undertakings). In addition, 1,074,942 units, corresponding to approximately 3.1 per cent of the Rights Issue, were subscribed for without unit rights. 6,051,001 units, corresponding to approximately 17.2 per cent of the Rights Issue, have been allocated to the parties that have provided guarantee undertakings. Thus, a total of 13,575,577 units, corresponding to approximately 38.7 per cent of the Rights Issue, have been subscribed for in the Rights Issue. Through the Rights Issue, Ziccum will receive SEK 11.7 million before deduction of issue costs.

Outcome of the Rights Issue
The Rights Issue comprised a maximum of 35,109,305 units. Each unit consisted of one (1) newly issued share and one (1) newly issued warrant of series TO 6 (together, a “Unit”). 6,449,634 Units, corresponding to approximately 18.4 per cent of the Rights Issue, have been subscribed for with unit rights (including subscription undertakings). In addition, 1,074,942 Units, corresponding to approximately 3.1 per cent of the Rights Issue, have been subscribed for without unit rights. 6,051,001 Units, corresponding to approximately 17.2 per cent of the Rights Issue, have been allocated to the parties who have provided guarantee undertakings. In total, 13,575,577 Units, corresponding to approximately 38.7 per cent of the Rights Issue, have thus been subscribed for in the Rights Issue. Through the Rights Issue, Ziccum will receive SEK 11.7 million before deduction of issue costs, which are estimated to amount to approximately SEK 3 million, provided that all guarantors choose to receive the compensation in cash.

“We can conclude that this capital raise has generated a lower contribution that we had hoped for. This is naturally a consequence of our current capital structure and the current market climate for our segment. We can however confirm the continued value generation in Ziccum, building the true company value based on the competitive advantages of our technology, and we are looking forward to bringing this exciting potential to realisation. With the highest possible intensity, we continue our efforts in regards to technical development of our platform and business development.”, comment Ann Gidner, CEO, and Jonas Ekblom, Chairman of the Board.

Notification regarding allocation
Allocation of Units has been made in accordance with the allocation principles described in the prospectus published in connection with the Rights Issue. Notification of allotment of Units subscribed for without unit rights will be made by sending a contract note to each subscriber. Allocated Units subscribed for without unit rights shall be paid in accordance with the instructions on the contract note.

Trading in BTU
Trading in BTU (Sw. betald tecknad unit) is currently taking place on Nasdaq First North Growth Market and will cease on 30 December 2024. BTUs will then be converted into shares and warrants of series TO 6.

Number of shares, share capital and dilution
Through the Rights Issue, the total number of shares in the Company will increase by 13,575,577 shares, from 15,958,775 shares to 29,534,352 shares, and the share capital will increase by SEK 2,262,596.166669, from SEK 2,659,795.833336 to SEK 4,922,392.000005, resulting in a dilution of approximately 46.0 per cent.

Through the Rights Issue, a total of 13,575,577 warrants of series TO 6 will be issued. If all these warrants are exercised for subscription of shares, the number of shares in Ziccum will increase by 13,575,577 shares and the share capital will increase by SEK 2,262,596.166669, resulting in an additional dilution of approximately 31.5 per cent.

Advisors
Vator Securities AB is acting as financial advisor and issuing agent and Fredersen Advokatbyrå AB is acting as legal advisor to Ziccum in connection with the Rights Issue.

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in units, shares, warrants or other securities in Ziccum. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for units, shares or warrants in Ziccum has only been made through the prospectus published by the Company on 20 November 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and published on the Company's website. The Swedish Financial Supervisory Authority's approval of the prospectus shall not be construed as an approval of the Company's shares, warrants or other securities. This press release is not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 (“Prospectus Regulation”) and has not need approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Ziccum. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable law or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in contravention of this guidance may constitute a breach of applicable securities laws.

About Ziccum

Ziccum announces outcome of rights issue

Ziccum offentliggör utfall i företrädesemission

Ziccum AB (publ) (”Ziccum” eller ”Bolaget”) meddelar att Bolagets företrädesemission av units (”Företrädesemissionen”), i vilken teckningsperioden löpte ut den 10 december 2024, har avslutats. Den slutliga sammanräkningen visar att 6 449 634 units, motsvarande cirka 18,4 procent av Företrädesemissionen, har tecknats med stöd av uniträtter (inklusive teckningsåtaganden). Därutöver tecknades 1 074 942 units utan stöd av uniträtter, motsvarande cirka 3,1 procent av Företrädesemissionen. 6 051 001 units, motsvarande cirka 17,2 procent av Företrädesemissionen, har tilldelats de parter som ställt emissionsgarantier. Totalt har således 13 575 577 units, motsvarande cirka 38,7 procent av Företrädesemissionen, tecknats i Företrädesemissionen. Genom Företrädesemissionen tillförs Ziccum 11,7 miljoner kronor före avdrag för emissionskostnader.

Utfall i Företrädesemissionen
Företrädesemissionen omfattade högst 35 109 305 units. Varje unit bestod av en (1) nyemitterad aktie och en (1) nyemitterad teckningsoption av serie TO 6 (tillsammans, en ”Unit”). 6 449 634 Units, motsvarande cirka 18,4 procent av Företrädesemissionen, har tecknats med stöd av uniträtter (inklusive teckningsåtaganden). Därutöver har 1 074 942 Units, motsvarande cirka 3,1 procent av Företrädesemissionen, tecknats utan stöd av uniträtter. 6 051 001 Units, motsvarande cirka 17,2 procent av Företrädesemissionen, har tilldelats de parter som ställt emissionsgarantier. Totalt har således 13 575 577 Units, motsvarande cirka 38,7 procent av Företrädesemissionen, tecknats i Företrädesemissionen. Genom Företrädesemissionen tillförs Ziccum 11,7 miljoner kronor före avdrag för emissionskostnader, vilka beräknas uppgå till cirka 3 miljoner kronor, förutsatt att alla garanter väljer att erhålla ersättningen kontant.

”Vi kan konstatera att denna kapitalanskaffning skapat ett lägre tillskott än vad vi hade hoppats på. Detta är givetvis bland annat en konsekvens av vår befintliga kapitalstruktur och det rådande läget på kapitalmarknaden för vårt segment. Samtidigt kan vi bekräfta att Ziccum fortsätter att bygga sitt verkliga värde baserat på de konkurrensfördelar som teknologin erbjuder, och vi ser fram emot att realisera denna spännande potential. Vi fortsätter med högsta möjliga intensitet vårt arbete med teknisk utveckling av plattformen och affärsutveckling.”, kommenterar VD Ann Gidner och Styrelseordförande Jonas Ekblom.

Meddelande om tilldelning
Tilldelning av Units har skett i enlighet med de tilldelningsprinciper som beskrivits i det prospekt som publicerades i samband med Företrädesemissionen. Meddelande om tilldelning av Units tecknade utan stöd av uniträtter kommer att ske genom att en avräkningsnota skickas till respektive tecknare. Tilldelade Units tecknade utan stöd av uniträtter ska betalas i enlighet med instruktionerna på avräkningsnotan.

Handel med BTU
Handel med BTU (betald tecknad unit) bedrivs för närvarande på Nasdaq First North Growth Market och kommer att upphöra den 30 december 2024. BTU omvandlas då till aktier och teckningsoptioner av serie TO 6.

Antal aktier och aktiekapital samt utspädning
Genom Företrädesemissionen ökar det totala antalet aktier i Bolaget med 13 575 577 aktier, från 15 958 775 aktier till 29 534 352 aktier, och aktiekapitalet ökar med 2 262 596,166669 kronor, från 2 659 795,833336 kronor till 4 922 392,000005 kronor, innebärande en utspädning om cirka 46,0 procent.

Genom Företrädesemissionen kommer totalt 13 575 577 teckningsoptioner av serie TO 6 att emitteras. Om samtliga dessa teckningsoptioner nyttjas för teckning av aktier kommer antalet aktier i Ziccum att öka med 13 575 577 aktier och aktiekapitalet öka med 2 262 596,166669 kronor innebärande en ytterligare utspädning om cirka 31,5 procent.

Rådgivare
Vator Securities AB agerar finansiell rådgivare och emissionsinstitut och Fredersen Advokatbyrå AB agerar legal rådgivare till Ziccum i samband med Företrädesemissionen.

Om Ziccum

Ziccum offentliggör utfall i företrädesemission

Ziccum offentliggör preliminärt utfall i företrädesemission

Ziccum AB (publ) (”Ziccum” eller ”Bolaget”) offentliggör idag det preliminära utfallet i den företrädesemission av units (”Företrädesemissionen”) i vilken teckningsperioden löpte ut den 10 december 2024. Det preliminära utfallet indikerar att Företrädesemissionen tecknades till cirka 21,4 procent. Således indikerar det preliminära utfallet att garantiåtaganden om preliminärt 6 051 000 units, motsvarande cirka 17,2 procent av erbjudna units, kommer att utnyttjas.

Teckningsperioden i Företrädesemissionen som omfattade högst 35 109 305 units, bestående av aktier och teckningsoptioner serie TO 6, avslutades den 10 december 2024. Det preliminära utfallet indikerar att teckningar med och utan stöd av uniträtter uppgår till sammanlagt 7 524 576 units, motsvarande cirka 21,4 procent av Företrädesemissionen. Således indikerar det preliminära utfallet att garantiåtaganden om preliminärt 6 051 000 units, motsvarande cirka 17,2 procent av erbjudna units, kommer att utnyttjas.

Det slutliga utfallet i Företrädesemissionen förväntas offentliggöras den 12 december 2024.

Rådgivare
Vator Securities AB agerar finansiell rådgivare och emissionsinstitut och Fredersen Advokatbyrå AB agerar legal rådgivare till Ziccum i samband med Företrädesemissionen.

Om Ziccum

Ziccum offentliggör preliminärt utfall i företrädesemission

1 2 3 4 … 31 32 33

Posts navigation